Testicular torsion

Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform

Retrieved on: 
Thursday, March 30, 2023
Learning, Male, Sustain, Disability, Quality of life, Phase II, Pain, Testicular torsion, Patient, Urology, Nonsteroidal anti-inflammatory drug, Therapy, Standard of care, Health Canada, CSP, Pharmaceutical industry

Sustained Therapeutics' first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.

Key Points: 
  • Sustained Therapeutics' first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.
  • This Phase II trial will explore the possibility of repeated treatments, and will compare the reduction in pain to Standard of Care for this condition.
  • This Phase II trial of ST-01 received regulatory clearance from Health Canada in December 2022, and the company moved quickly to begin screening and enrolling patients.
  • Those interested in participating in the Canadian-based trial or learning more about it may contact Lesley Parker, VP Clinical Operations at Sustained Therapeutics, at [email protected]
    This second trial complements Sustained Therapeutics' ongoing Phase II trial of ST-01 in the treatment of acute post-operative pain.